Acalabrutinib

Acalabrutinib is a new oral Bruton's tyrosine kinase (BTK) inhibitor, which is mainly used to treat hematological malignancies such as chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

1. Drug name

1. Generic name: Acalabrutinib Capsules

2. Trade name: Calque nce (original drug)

2. Indications of

Acalabrutinib is used to treat specific hematological malignancies, such as chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). .

3. Specifications and properties of

Specifications: 100mg/capsule (capsule form).

IV. The main ingredient of

Active ingredient: Acalabrutinib.

5. U200c Usage and Dosage

1. Conventional dosage: Take 100mg orally, twice a day (about 12 hours apart).

2. Dosage adjustment: If serious adverse reactions (such as bleeding, infection, etc.) occur, the dosage should be reduced or the medication should be suspended according to the doctor's advice.

6. Precautions for taking

1. U200c before and after meals: It is recommended to take it at a fixed time. There is no clear limit on whether it needs to be taken on an empty stomach or after a meal.

2. Missed dose of : If the missed dose does not exceed 3 hours, you can take it immediately; if it exceeds 3 hours, skip it and take the next dose as originally planned.

3. Vomiting : If you vomit after taking the medicine, there is no need to take a supplementary dose. Wait for the next planned dose.

VII. U200c Medication for Special Populations

1. Hepatic/renal insufficiency : Use with caution and the dose may need to be adjusted.

2. Pregnant and lactating women : Disabled, may cause harm to the fetus or infant.

8. Adverse reactions of

Common adverse reactions include headache, diarrhea, fatigue, muscle pain, etc.; serious adverse reactions may be bleeding, arrhythmia or infection.

9. Contraindications of

1. It is prohibited for those who are allergic to acalabrutinib or excipients.

2. Caution is required when used in combination with strong CYP3A inhibitors/inducers (it may affect drug efficacy or toxicity).

10. drug interactions

1. CYP3A inhibitors (such as ketoconazole) may increase the plasma concentration of acalabrutinib.

2. The combined use of anticoagulants (such as warfarin) may increase the risk of bleeding.

11. storage method

Save at room temperature (20-25°C) and avoid moisture and light.